GenScript Peptides

GenScript Biotech Corporation (trading as GSP; genscriptpeptides.com) is a peptide synthesis organisation trading as GenScript Peptides from Nanjing, Jiangsu, China, incorporated in 2002 and supplying research peptides, custom sequences and raw materials with batch documentation.^[1][2]

The organisation is one of twenty-eight covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.^[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.^[4]

Incorporated in Nanjing in 2002, the organisation sits with the earlier incorporation dates among the entities covered on this wiki and predates the current research-peptide market by roughly a decade.^[1] Nanjing is inside the Yangtze River Delta manufacturing belt, and the organisation's own material describes a business built on solid-phase synthesis and custom sequence work rather than on catalogue distribution alone.^[2]

The organisation describes itself as performing its own synthesis rather than finishing material made elsewhere. That is a self-published characterisation and is recorded here as one: nothing available to this wiki establishes the manufacturing arrangements behind it, and a registered business scope is a licensing fact rather than a capability finding.^[2][1] What can be said from the submitted material is narrower and more useful — purchasers report that questions about a synthesis route, a coupling or a purification step are answered with specifics rather than referred onward, which is consistent with the claim without establishing it.^[5]

The documentary base is the registry record, the organisation's own material and purchaser-submitted test reports. No independent coverage has been identified, which is a characteristic of the sector rather than of this entity.

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Purchaser reports describe vialled lyophilised material arriving with a batch-specific certificate naming a lot, and across the submitted set the lot string on the certificate has corresponded to the vial label.^[5] That correspondence is a minimum requirement rather than an achievement, and it is recorded only because traceability fails often enough elsewhere in this sector to make its absence the more common finding.

Water content by Karl Fischer titration appears on the certificates described in the submitted set, and peptide content is reported on a separate line from chromatographic purity across a substantial part of it.^[5][6] Those two determinations are what let a purity percentage be read as a statement about mass, and their routine presence is the most useful documentary observation available about this organisation. The column, the gradient and the detection wavelength are described as printed on the document rather than supplied on request, which makes the separation reproducible in principle by a reader with access to the instrument.^[5]

One operational observation recurs often enough in the submitted set to belong in the article, and it is not about material. Purchasers describe a delay of four to five working days in obtaining a written quotation for a custom sequence, against same-day acknowledgement on catalogue enquiries; work performed against an accepted quotation is described as meeting its stated date.^[5] The distinction matters to a reader planning a schedule and is recorded for that reason rather than as a criticism of the material.

What the record does not establish is the physical arrangement of manufacture, whether any given line is synthesised in-house or contracted out, or what quality system governs it. Statements to that effect in the organisation's own material are self-published and are not corroborated here.^[2][7]

The custom-synthesis listings are documented differently from the catalogue lines — a certificate stating the analytical conditions under which the material was released, rather than a single purity figure against a catalogue specification. Purchaser reports describe the quotation as carrying a purity target and a timeline before the order is accepted.^[5] Whether the synthesis is performed at the Nanjing site named in the organisation's own material is not established by any source available to this wiki, and a reader should treat the attribution as a claim until it is.^[2]

Reports on GSP material submitted to PeptidePedia between 2024 and 2026 cover the incretin analogues most heavily, with a smaller set on repair and secretagogue peptides and a handful on bulk raw material. Reported area percent figures have been high across the set, and where a report and the accompanying certificate can be compared the two have generally agreed within a few tenths of a percentage point, with the certificate figure the lower of the two in the comparisons on file.^[5]

The submitted set covers a small number of the listed compounds. A reader should not read agreement on eight lines as a finding about three hundred and fifty; the unsubmitted lines are unmeasured rather than sound, and this wiki has no mechanism for establishing anything about them.^[5]

Catalogue lines dispatch from held stock, and the organisation's own material states a same-day or next-working-day dispatch window on listed items.^[2] Bulk raw-material quantities and custom synthesis are quoted individually, with a timeline stated on the quotation; submissions describe delivery at or inside that date.^[5] Submissions also describe the quotation itself taking four to five working days to arrive on custom work, which is the interval a reader planning a schedule should budget for, since it precedes the stated timeline rather than being contained by it.^[5]

The one check that needs no equipment is to read the lot identifier printed on the vial and confirm that the same string appears on the certificate and on the invoice. Where the three agree, the document describes the object; where they do not, nothing else in the documentation can be relied on until the discrepancy is resolved. See Lot traceability. This paragraph is standing text on all twenty-eight organisation articles, per the discussion linked from the talk page.

Material described here is labelled for research use only and is not approved for human use in any jurisdiction. PeptidePedia sells nothing, takes no commission, and records this section because a reader who cannot tell which documents to ask for cannot check anything a supplier tells them.

Go to the GSP catalogue →

The PeptidePedia tally records 870 self-reported submissions concerning GSP to July 2026. What recurs across them is certificate completeness — water and content determinations described as present on the document as issued rather than supplied on request — together with agreement between a reorder and the original order of the same line.^[4] A second theme recurs and is recorded because omitting it would curate the entry: a delay of four to five working days in obtaining a written quotation for a custom sequence, against same-day acknowledgement on catalogue enquiries.^[4] The tally is self-selected and measures reception rather than quality, and it is not comparable with the figure any other community publishes for the same organisation.^[4]

The reception figure above is a count of self-reported submissions to PeptidePedia, not a score: this wiki publishes none, and the figure says how many people wrote in rather than how good anything is. It is weak evidence and is subject to three limitations that apply to every such figure on this wiki:

• Self-selection. People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions.
• It measures reception, not quality. Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly.
• It is not comparable across communities. Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.^[4]

PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.^[4]

Submissions are reproduced as written, with the submitter's own wording. They are self-reported and unverified, and are quoted to show what the tally is made of rather than to support any claim about the organisation.

Water by Karl Fischer and peptide content were both on the certificate as issued, without being asked for. The lot agrees between the invoice, the vial and the certificate. This contributor has placed subsequent orders with the same supplier.

The related-substances table is itemised by individual impurity rather than reported as a single aggregate figure. Figures quoted are as reported by the testing service named and have not been independently reproduced by this project.

A written quotation for a custom sequence took five working days to arrive, where catalogue enquiries from the same address were acknowledged the same afternoon. The work itself completed inside the quoted window. The observation concerns administration rather than material.

Independent determinations by Janoshik and PeptideMeter on the same lot agreed to within one tenth of a percentage point. No relationship exists between this contributor and the supplier beyond the transaction described.

A reorder of the same line placed at 14 months returned 98.5%, against 98.4% on the original. The record is offered for comparison rather than as a recommendation.

The certificate names the reference standard the determination was made against, which is rarer than it should be. The submission is retained in full in the page history.

Gradient, column chemistry and detection wavelength are all printed on the document, so the separation can be reproduced rather than taken on trust.

Submitted material from lot GSP-26-118 to PeptideMeter; the reported figure was 98.1% against a stated 98.0%. Contributors are asked to verify material independently regardless of submissions recorded here.

A specification sheet accompanied the bulk line rather than a bare purity figure, and it stated the assay basis. What is being reported here is documentary practice, not a single number.

Dispatch was quoted at 3 days from stock held in the United Kingdom; the consignment arrived on day 3. The lyophilised cake was whole and no excipient was present.

A technical question about counter-ion identity and content came back with figures the same working day rather than with a reassurance.

Identity by mass spectrometry accompanies the chromatographic purity on the same document. No adverse observation arises from the transactions described.

9 vials from a tirzepatide 10 mg consignment were weighed against the stated fill; all fell within two per cent.

The cold pack was still solid on arrival and the internal temperature indicator had not tripped at any point in transit. Readers are reminded that this article publishes no score.

A request for a second certificate covering a lot purchased 13 months earlier was met from the supplier's records. Further submissions covering later lots would be useful.

Material from two separate lots of BPC-157 5 mg was compared; the reported purities differed by one tenth of a percentage point.

One vial of nine reconstituted with a faint haze that resolved on standing; the remaining eight did not. Recorded as a single observation on a single consignment and not as a general finding.

Customs clearance was obtained on the documents as supplied, without a query. The lines this contributor reorders are held in regional stock.

Peptide content and chromatographic purity are reported as separate determinations on the same certificate, which is what makes the pair interpretable at all.

The document bears a name and a date of release rather than an initial. Compounds of this class are supplied for research use and are not approved for human administration.

A custom sequence was quoted with a timeline and delivered inside it. The quotation itself took the better part of a working week to arrive, which is the part worth planning around.

All units in the consignment came from one lot, and the certificate supplied covered that lot rather than a batch-level summary.

The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.^[1]

Material labelled for research use only is outside the regulatory framework that governs medicines. Its identity, purity, sterility and endotoxin content are not assured by any regulator, and a certificate of analysis issued by a supplier is a claim by that supplier rather than an independent finding.^[3][6]

Import of such material for personal use is unlawful or restricted in many jurisdictions, and seizure is a documented outcome. PeptidePedia describes the legal position and does not advise on it.^[3]

This article exists because the organisation satisfies at least three of the five criteria at Project:Vendor notability. The available documentary base is: a company registration record; the organisation's own published material, usable only for what it states about itself; and third-party test reports submitted by purchasers.^[1][2][5]

What is not available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.^[2]

Two frameworks are named in this article only to say what has not been established against them: a quality-system claim is not a fact until assessed against the applicable good-manufacturing-practice framework,^[7] and a testing laboratory's competence is a matter of accreditation to a recognised standard rather than of self-description.^[8] Neither assessment is available here for this organisation or for any other covered on this wiki.

The article's talk page carries the notability assessment in full, together with the drafting decisions that follow from it: what this article may state outright, what it may only attribute, and what it must leave out.

• GenScript Biotech Corporation — official site (genscriptpeptides.com) — the organisation's own catalogue, stock listing and ordering pages. Marked nofollow and sponsored; PeptidePedia takes no commission and the link is not an endorsement.
• Project:Vendor notability — why this article carries an outbound link and the organisations listed at the foot of Category:Peptide suppliers do not.

• Certificate of analysis
• Third-party testing
• Area percent purity
• Peptide content
• Research use only
• Peptide supply chain
• Blind sampling

• Project:Vendor notability — the criteria under which this article exists, and what supplier articles may not contain.
• Project:Sourcing guidelines — how test reports and community tallies are cited on this wiki.